Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes

Immunology and Cell Biology

Volumn 92, Issue 2, 2014, Pages 191-199

  Pittelli, Maria ^a   Cavone, Leonardo ^a   Lapucci, Andrea ^a   Oteri, Claudia ^a   Felici, Roberta ^a   Niccolai, Elena ^b   Amedei, Amedeo ^b   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

FK866; Lymphocyte; NAD; NAMPT

Indexed keywords

ACRYLAMIDE DERIVATIVE; CYTOKINE; N-(4-(1-BENZOYLPIPERIDIN-4-YL)BUTYL)-3-(PYRIDIN-3-YL)ACRYLAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, MOUSE; PARP1 PROTEIN, HUMAN; PARP1 PROTEIN, MOUSE; PIPERIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MALE; MOUSE;

ACRYLAMIDES; ANIMALS; APOPTOSIS; CELL SURVIVAL; CYTOKINES; HUMANS; MALE; MICE; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84893841124     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.85     Document Type: Article

References (32)

1. Ziegler M, Niere M. NAD+ surfaces again. Biochem J 2004; 382: e5-e6.
2. Koch-Nolte F, Haag F, Guse AH, Lund F, Ziegler M. Emerging roles of NAD+ and its metabolites in cell signaling. Sci Signal 2009; 2: mr1.
3. Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome-a key determinant of cancer cell biology. Nat Rev Cancer 2012; 12: 741-752.
4. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci 2007; 32: 12-19.
5. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 2009; 20: 130-138.
6. Montecucco F, Cea M, Bauer I, Soncini D, Caffa I, Lasiglie D et al. Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets 2013; 14: 637-643.
7. Galli U, Travelli C, Massarotti A, Fakhfouri G, Rahimian R, Tron GC et al. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. J Med Chem 2013; 56: 6279-6296.
8. Hasmann M, Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 2003; 63: 7436-7442. (Pubitemid 37413486)
9. Billington RA, Genazzani AA, Travelli C, Condorelli F. NAD depletion by FK866 induces autophagy. Autophagy 2008; 4: 385-387. (Pubitemid 351458108)
10. Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT et al. Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity. Blood 2013; 122: 1243-1255.
11. Thakur BK, Dittrich T, Chandra P, Becker A, Kuehnau W, Klusmann JH et al. Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. Int J Cancer 2013; 132: 766-774.
12. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008; 181: 4685-4695.
13. Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 2009; 4: e7897.
14. Stone TW, Darlington LG. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol 2013; 169: 1211-1227.
15. D?Amours D, Desnoyers S, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342: 249-268. (Pubitemid 29425344)
16. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood 2012; 120: 3519-3529.
17. Holen K, Saltz LB, Hollywood E, Burk K, Hanauske AR. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest New Drugs 2008; 26: 45-51.
18. Pittelli M, Felici R, Pitozzi V, Giovannelli L, Bigagli E, Cialdai F et al. Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol Pharmacol 2011; 80: 1136-1146.
19. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 1147-1154. (Pubitemid 46718399)
20. Potaman VN, Shlyakhtenko LS, Oussatcheva EA, Lyubchenko YL, Soldatenkov VA. Specific binding of poly(ADP-ribose) polymerase-1 to cruciform hairpins. J Mol Biol 2005; 348: 609-615. (Pubitemid 40515673)
21. Lonskaya I, Potaman VN, Shlyakhtenko LS, Oussatcheva EA, Lyubchenko YL, Soldatenkov VA. Regulation of poly(ADP-ribose) polymerase-1 by DNA structurespecific binding. J Biol Chem 2005; 280: 17076-17083. (Pubitemid 41389171)
22. Rapizzi E, Fossati S, Moroni F, Chiarugi A. Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes. Mol Pharmacol 2004; 66: 890-898. (Pubitemid 39319461)
23. Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 2011; 13: 461-468.
24. Chiarugi A. PARP-1: killer or conspirator? The suicide hypothesis revisited. Trends Pharmacol Sci 2002; 23: 122-129.
25. Pittelli M, Formentini L, Faraco G, Lapucci A, Rapizzi E, Cialdai F et al. Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool. J Biol Chem 2010; 285: 34106-34114.
26. Pellicciari R, Camaioni E, Costantino G, Formentini L, Sabbatini P, Venturoni F et al. On the way to selective PARP-2 inhibitors. Design, synthesis, and preliminary evaluation of a series of isoquinolinone derivatives. ChemMedChem 2008; 3: 914-923.
27. Tan B, Young DA, Lu ZH, Wang T, Meier TI, Shepard RL et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications. J Biol Chem 2013; 288: 3500-3511.
28. Chang CH, Curtis JD, Maggi LB Jr., Faubert B, Villarino AV, O?Sullivan D et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013; 153: 1239-1251.
29. Frauwirth KA, Thompson CB. Regulation of T lymphocyte metabolism. J Immunol 2004; 172: 4661-4665. (Pubitemid 38456383)
30. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
31. Cavone L, Aldinucci A, Ballerini C, Biagioli T, Moroni F, Chiarugi A. PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult Scler 2011; 17: 794-807.
32. Shah T, Atwell M, Bird D, Lim CK, Peters TJ, Webster AD. Adenine nucleotide concentrations in peripheral blood lymphocytes from patients with common variable hypogammaglobulinaemia and B-cell chronic lymphatic leukaemia. J Clin Lab Immunol 1988; 26: 9-12.